Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Lutetium Lu 177 Dotatate

Review the clinical trials studying lutetium lu 177 dotatate on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-19 of 19

Testing Lutetium Lu 177 Dotatate in Patients with Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Status: Active
Location: 28 locations
Comparing Retreatment of 177Lu-DOTATATE PRRT versus the Usual Treatment in Patients with Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Status: Active
Location: 23 locations
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used with Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
Status: Active
Location: 25 locations
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer that has Neuroendocrine Cells
Status: Active
Location: 13 locations
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
Status: Active
Location: 7 locations
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Status: Active
Location: 5 locations
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Status: Active
Location: 7 locations
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Status: Active
Location: 5 locations
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
Status: Active
Location: 2 locations
Lutathera for the Treatment of Patients with Recurrent, Progressive or Refractory Central Nervous System Tumors and Meningiomas
Status: Active
Location: 2 locations
Dosimetry-Guided Lutathera for the Treatment of Unresectable and/or Metastatic Gastroenteropancreatic Neuroendocrine Tumors, LuMOD-ID Trial
Status: Active
Location: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa
Lutathera for the Treatment of Inoperable, Progressive Meningioma after External Beam Radiation Therapy
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Peptide Receptor Radionuclide Therapy before and after Surgery for the Treatment of Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumor
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
177Lu-DOTATATE and Fulvestrant for the Treatment of Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Patients with Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Status: Approved
Location: OHSU Knight Cancer Institute, Portland, Oregon
Using 64Cu-DOTATATE PET/CT for Treatment Planning of 177Lu-DOTATATE for Patients with Neuroendocrine Cancer
Status: Active
Location: 2 locations